China Vascular Grafts Market Size, Share and Outlook - Growth Analysis Report and Forecast Trends 2026-2030

The China vascular grafts market encompasses synthetic and biologic vascular prostheses used in open and endovascular surgeries to restore blood flow in occluded or aneurysmal vessels. The market covers aortic grafts for treating thoracic and abdominal aortic aneurysms and peripheral vascular grafts for lower-limb artery disease, among other applications. Valued at roughly $350 million in 2025, it represents one of the fastest-growing medical device segments in the Asia-Pacific region, fueled by China's rising burden of vascular disease and improving surgical adoption rates.

• •Estimated market value of ~$0.35 billion in 2025 with 6.8% annual growth trajectory through the early 2030s
• •Key clinical applications include aortic aneurysm repair, peripheral artery disease treatment, coronary artery bypass, and hemodialysis access for renal failure patients
• •Product categories span aortic vascular grafts (stent-grafts and tube grafts) and peripheral vascular grafts, with dominant materials including expanded polytetrafluoroethylene (ePTFE), Dacron (polyester), and biologic tissue grafts

China's demographic shift toward an older population is a primary catalyst, as cardiovascular and peripheral vascular diseases increase significantly with age. The rising prevalence of diabetes, hypertension, and chronic kidney disease, all major risk factors for vascular pathology, further expands the patient pool requiring graft-based interventions. Expanding healthcare insurance coverage, increased hospital infrastructure investment, and growing surgeon familiarity with endovascular techniques are collectively accelerating procedure volumes and market adoption.

• •Aging population: China's growing cohort of adults over 60 directly correlates with rising incidence of aortic aneurysms, peripheral artery disease, and coronary conditions requiring graft procedures
• •Lifestyle disease epidemic: Escalating rates of type 2 diabetes, obesity, and hypertension drive demand for peripheral vascular grafts and dialysis access grafts
• •Healthcare access expansion: Government investment in tier-2 and tier-3 hospital capabilities and broader insurance reimbursement are making vascular surgical procedures accessible to a wider patient population

The market is broadly segmented into aortic vascular grafts, covering tube grafts and aortic stent-grafts for aneurysm and dissection repair, and peripheral vascular grafts used in femoropopliteal, carotid, and renal artery procedures. By raw material, PTFE-based grafts hold the largest share due to biocompatibility and durability, though Dacron and biologic grafts maintain significant presence in certain aortic applications. Within China, tier-1 cities like Beijing, Shanghai, and Guangzhou lead in procedure volumes and adoption of advanced technologies, while tier-2 and tier-3 regions represent the fastest-expanding market opportunities as hospital capabilities improve.

• •Product split: Peripheral vascular grafts currently account for the larger volume segment, while aortic grafts (especially endovascular stent-grafts) represent the higher-value growth area
• •Material categories: ePTFE grafts dominate peripheral indications; Dacron and biologic grafts are preferred in certain aortic reconstructions; growing interest in off-the-shelf biologic conduits
• •Regional dynamics: Coastal and urban centers drive early adoption, while inland and western provinces present emerging demand as cardiovascular surgical infrastructure develops

What are the recent trends and outlook?

The market is moving toward minimally invasive endovascular procedures that reduce hospital stays and recovery times, driving demand for advanced stent-graft technologies and drug-eluting or coated graft surfaces. Regulatory reforms in China are streamlining device approvals and encouraging domestic innovation, which should accelerate local product development and market penetration over the forecast period. Integration of imaging guidance, robotics-assisted surgery, and personalized graft sizing are emerging as differentiators. The market is projected to sustain approximately 6.8% annual growth through 2033, reaching substantially higher absolute value as procedure volumes continue scaling across China's hospital system.

• •Endovascular shift: Growing preference for catheter-based stent-graft deployment over open surgical reconstruction is expanding the aortic and peripheral stent-graft submarket
• •Domestic innovation push: China's NMPA approval pathways and local manufacturing incentives are enabling domestic companies to develop and commercialize competitively priced vascular grafts, particularly for dialysis access
• •Clinical outcome focus: Emerging emphasis on long-term patency rates, infection-resistant materials, and patient-specific graft configurations is shaping next-generation product development